Evaluating Complication Rates in Post-Weight-Loss Body Contouring: Comparing Surgery, GLP-1 Pharmacotherapy, Combination, and Lifestyle Approaches
Posted inDiabetes & Endocrinology news Plastic Surgery

Evaluating Complication Rates in Post-Weight-Loss Body Contouring: Comparing Surgery, GLP-1 Pharmacotherapy, Combination, and Lifestyle Approaches

This study investigates postoperative complication rates following body-contouring surgery among patients with differing weight-loss methods, revealing that weight-loss modality does not affect complications, while BMI and diabetes at surgery are key predictors.
Glucagon-Like Peptide 1 Receptor Agonists, Mortality, and Cardiovascular Outcomes in Serious Mental Illness: A Comprehensive Review
Posted inCardiology Clinical Updates Diabetes & Endocrinology news

Glucagon-Like Peptide 1 Receptor Agonists, Mortality, and Cardiovascular Outcomes in Serious Mental Illness: A Comprehensive Review

GLP-1 receptor agonists reduce mortality and cardiovascular events more effectively than SGLT2 inhibitors in serious mental illness (SMI), with early benefits and consistent effects across bipolar disorder, major depression, and schizophrenia. Semaglutide shows particular promise in improving cardiometabolic health.
GLP-1 Receptor Agonists May Reduce Hospital Admissions for Alcohol and Substance Use Disorders: Insights from a Swedish Nationwide Study
Posted inDiabetes & Endocrinology news Psychiatry

GLP-1 Receptor Agonists May Reduce Hospital Admissions for Alcohol and Substance Use Disorders: Insights from a Swedish Nationwide Study

This Swedish register-based study reveals that GLP-1 receptor agonists are associated with significantly reduced hospitalisations for alcohol and substance use disorders during treatment, with some lasting benefits after discontinuation of therapy for alcohol use disorder.
Crowded Optic Discs and Risk Stratification of NAION in GLP-1 Receptor Agonist Users: Insights from a Large Multicenter Study
Posted inDiabetes & Endocrinology news Ophthalmology

Crowded Optic Discs and Risk Stratification of NAION in GLP-1 Receptor Agonist Users: Insights from a Large Multicenter Study

This large multicenter study reveals that nonarteritic anterior ischemic optic neuropathy (NAION) patients exposed to GLP-1 receptor agonists exhibit similar optic disc crowding compared to nonexposed patients, with smaller cup-to-disc ratios strongly correlating with increased NAION risk.
Evaluating the Risk of Anterior Ischemic Optic Neuropathy with GLP-1 Receptor Agonists in Type 2 Diabetes: Insights from a Swedish Nationwide Cohort Study
Posted inDiabetes & Endocrinology news Ophthalmology

Evaluating the Risk of Anterior Ischemic Optic Neuropathy with GLP-1 Receptor Agonists in Type 2 Diabetes: Insights from a Swedish Nationwide Cohort Study

A large Swedish cohort study assesses whether glucagon-like peptide-1 receptor agonists increase the risk of anterior ischemic optic neuropathy in type 2 diabetes. Although a borderline elevated relative risk was observed, absolute incidence remained low and confounding factors likely influenced results.
GLP-1 Receptor Agonists and the Risk of Ischemic Optic Neuropathy in Type 2 Diabetes: Evidence from a Target Trial Emulation
Posted inDiabetes & Endocrinology news Ophthalmology

GLP-1 Receptor Agonists and the Risk of Ischemic Optic Neuropathy in Type 2 Diabetes: Evidence from a Target Trial Emulation

This study evaluates the association between GLP-1 receptor agonists and ischemic optic neuropathy risk compared to SGLT2 and DPP-4 inhibitors, revealing a small but statistically significant increased risk with GLP-1RAs, particularly among older men with cardiovascular or eye conditions.
Glucagon-like Peptide-1 Receptor Agonists Versus Dipeptidyl Peptidase-4 Inhibitors Following Liver Resection for Hepatocellular Carcinoma in Type 2 Diabetes: Insights from a Target Trial Emulation Study
Posted inClinical Updates news

Glucagon-like Peptide-1 Receptor Agonists Versus Dipeptidyl Peptidase-4 Inhibitors Following Liver Resection for Hepatocellular Carcinoma in Type 2 Diabetes: Insights from a Target Trial Emulation Study

Postoperative GLP-1RA initiation after liver resection for hepatocellular carcinoma in type 2 diabetes patients is associated with improved recurrence-free and overall survival compared to DPP-4 inhibitors, indicating potential incremental benefits of GLP-1RAs in this setting.